98 results
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc.
1 Aug 24
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
6:03am
Nephritis
Lupus Nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. LN affects
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc.
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
erythematosus (SLE), a chronic and complex autoimmune disease. LN affects approximately 120,000 people in the U.S. and disproportionately affects women
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc.
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
with active LN without reliance on chronic high-dose glucocorticoids. It is the only clinical program to include three years of LN treatment and follow-up … (SLE), a chronic and complex autoimmune disease. LN affects approximately 120,000 people in the U.S. and disproportionately affects women and people
8-K
EX-99.1
wevoyh0485k
5 Jan 24
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
6:02am
8-K
EX-99.1
7rwyvyl
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
EX-99.1
6duzr8
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
8-K
EX-99.1
1z2qxf whpbay
4 May 23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
6:06am
8-K
EX-99.2
9cx006u7jkfvgmjw3rre
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am
8-K
EX-99.1
8pynesjztw f6w5c
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am
8-K
EX-99.1
46p08uglkt80wt
3 Nov 22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
6:04am
8-K
EX-99.1
tmetirou
4 Aug 22
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
6:07am
8-K
EX-99.1
e9pvmd5fg no
10 May 22
Aurinia Reports First Quarter 2022 Financial and Operational Results
6:06am
8-K
EX-99.1
s78cw1vp4m8zrmz58
28 Feb 22
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
6:08am
8-K/A
EX-99.1
6gbc357kj4r
7 Jan 22
CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin Updated January 2022
4:10pm
8-K
EX-99.1
cya8l198 fy
9 Dec 21
Regulation FD Disclosure
6:31am